Characterizing the binding mechanisms of castration-resistant prostate cancer therapeutics to the intrinsically disordered N-terminal domain of the androgen receptor
表征去势抵抗性前列腺癌治疗药物与雄激素受体本质上无序的 N 端结构域的结合机制
基本信息
- 批准号:10656552
- 负责人:
- 金额:$ 40.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-15 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:Androgen ReceptorAntineoplastic AgentsBindingBiologicalBiophysicsCellular AssayClinicalClinical TrialsDevelopmentDiseaseDrug DesignDrug TargetingHumanLaboratoriesMeasurementMediatingMethodsMolecularMolecular ConformationN-terminalNMR SpectroscopyPathway interactionsPharmaceutical PreparationsPharmacologic SubstancePhysical condensationPhysiologicalProteinsProteomeResearchRoleStructureTherapeuticTherapeutic InterventionWorkcastration resistant prostate cancerdrug candidateexperimental studyhuman diseaseinhibitorinsightnovelprotein misfoldingrational designsimulationsmall moleculetherapeutic targetthree dimensional structure
项目摘要
Project Summary /Abstract
Intrinsically disordered proteins (IDPs), which lack a fixed three-dimensional structure under
physiological conditions, represent ~40% of the human proteome, have crucial functional roles in a variety
of biological pathways and biomolecular assemblies and are implicated in a large number of human
diseases. As IDPs populate a dynamic conformational ensemble of rapidly interconverting structures in
solution, and cannot be represented by a single dominant conformation, or even a small number of
substantially populated conformations, they are not suitable targets for conventional structure-based drug
design methods. If it becomes possible to target IDPs with small molecule drugs, the druggable proteome
will be dramatically expanded and therapeutic interventions may become accessible for currently
untreatable diseases
The PI’s laboratory utilizes an integrated computational and experimental research strategy to combine
state-of-the-art all-atom molecular simulations with experimental measurements from NMR spectroscopy
and other biophysical experiments to obtain atomistic descriptions of the dynamic binding mechanisms of
IDPs and uses insights form these binding mechanisms to predict and rationally design novel binding
interactions. This proposal focuses on applying this integrated computational and experimental approach
to elucidate the binding mechanisms of small molecule drug candidates that target that intrinsically
disordered domain of the androgen receptor and have entered clinical trials for castration resistant prostate
cancer (CRPC). These binding mechanisms will be used to inform the rational design more potent and
selective androgen receptor inhibitors and more effective CRPC therapeutics
. This proposal describes a
remarkable opportunity to draw connections between molecular binding mechanisms studied by molecular
simulations and NMR, biological activity observed in cellular assays, and clinical results from human
CRPC drug trials.
This proposal will initiate a sustainable long-term research effort to combine computational and
experimental methods to study the dynamic interactions of IDPs in a variety of cellular and pharmaceutical
contexts. This research effort will stimulate the development of robust platforms to integrate computational
and experimental methods that will dramatically increase the number of proteins amenable to structural and
mechanistic characterization and pharmaceutical targeting and will provide new avenues to therapeutic
interventions in diseases associated with aberrant biological interactions of IDPs such as those mediated by
biomolecular condensate formation and protein misfolding.
项目摘要/摘要
项目成果
期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Molecular Basis of Small-Molecule Binding to α-Synuclein.
- DOI:10.1021/jacs.1c07591
- 发表时间:2022-02-16
- 期刊:
- 影响因子:15
- 作者:Robustelli P;Ibanez-de-Opakua A;Campbell-Bezat C;Giordanetto F;Becker S;Zweckstetter M;Pan AC;Shaw DE
- 通讯作者:Shaw DE
Small molecules targeting the disordered transactivation domain of the androgen receptor induce the formation of collapsed helical states.
靶向雄激素受体无序反式激活结构域的小分子会诱导崩溃的螺旋状态的形成。
- DOI:10.1038/s41467-022-34077-z
- 发表时间:2022-10-27
- 期刊:
- 影响因子:16.6
- 作者:
- 通讯作者:
Rational optimization of a transcription factor activation domain inhibitor.
- DOI:10.1038/s41594-023-01159-5
- 发表时间:2023-12
- 期刊:
- 影响因子:16.8
- 作者:Basu, Shaon;Martinez-Cristobal, Paula;Frigole-Vivas, Marta;Pesarrodona, Mireia;Lewis, Michael;Szulc, Elzbieta;Banuelos, C. Adriana;Sanchez-Zarzalejo, Carolina;Bielskute, Stase;Zhu, Jiaqi;Pombo-Garcia, Karina;Garcia-Cabau, Carla;Zodi, Levente;Dockx, Hannes;Smak, Jordann;Kaur, Harpreet;Batlle, Cristina;Mateos, Borja;Biesaga, Mateusz;Escobedo, Albert;Bardia, Lidia;Verdaguer, Xavier;Ruffoni, Alessandro;Mawji, Nasrin R.;Wang, Jun;Obst, Jon K.;Tam, Teresa;Brun-Heath, Isabelle;Ventura, Salvador;Meierhofer, David;Garcia, Jesus;Robustelli, Paul;Stracker, Travis H.;Sadar, Marianne D.;Riera, Antoni;Hnisz, Denes;Salvatella, Xavier
- 通讯作者:Salvatella, Xavier
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Paul Robustelli其他文献
Paul Robustelli的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Paul Robustelli', 18)}}的其他基金
Characterizing the binding mechanisms of castration-resistant prostate cancer therapeutics to the intrinsically disordered N-terminal domain of the androgen receptor
表征去势抵抗性前列腺癌治疗药物与雄激素受体本质上无序的 N 端结构域的结合机制
- 批准号:
10275183 - 财政年份:2021
- 资助金额:
$ 40.96万 - 项目类别:
相似海外基金
Delays in Acquisition of Oral Antineoplastic Agents
口服抗肿瘤药物的获取延迟
- 批准号:
9975367 - 财政年份:2020
- 资助金额:
$ 40.96万 - 项目类别:
Eliminate the difficulty of venous puncture in patients receiving antineoplastic agents - Development of a new strategy for the prevention of induration-
消除接受抗肿瘤药物的患者静脉穿刺的困难 - 制定预防硬结的新策略 -
- 批准号:
16K11932 - 财政年份:2016
- 资助金额:
$ 40.96万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular mechanisms of the antineoplastic agents inhibiting DNA replication and their applications to cancer patient treatmen
抗肿瘤药物抑制DNA复制的分子机制及其在癌症患者治疗中的应用
- 批准号:
19591274 - 财政年份:2007
- 资助金额:
$ 40.96万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
PNET EXPERIMENTAL THERAPEUTICS--ANTINEOPLASTIC AGENTS AND TREATMENT DELIVERY
PNET 实验治疗——抗肿瘤药物和治疗实施
- 批准号:
6346309 - 财政年份:2000
- 资助金额:
$ 40.96万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
2885074 - 财政年份:1999
- 资助金额:
$ 40.96万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
6174221 - 财政年份:1999
- 资助金额:
$ 40.96万 - 项目类别: